selected publications
-
academic article
-
The prognostic value of serum IL-6 and YKL-40 in patients with metastatic colorectal cancer..
Journal of Clinical Oncology.
35.
2017
Tissue MicroRNA profiles as diagnostic and prognostic biomarkers in patients with resectable pancreatic ductal adenocarcinoma and periampullary cancers.
Biomarker Research.
5.
2017
The Prognostic Value of Plasma YKL-40 in Patients With Chemotherapy-Resistant Ovarian Cancer Treated With Bevacizumab.
International Journal of Gynecological Cancer.
26.
2016
MicroRNA Expression in Formalin-fixed Paraffin-embedded Cancer Tissue: Identifying Reference MicroRNAs and Variability.
BMC Cancer.
15.
2015
Tissue MicroRNAs as Predictors of Outcome in Patients with Metastatic Colorectal Cancer Treated with First Line Capecitabine and Oxaliplatin with or without Bevacizumab.
PLoS ONE.
9.
2014
-
dataset
-
Additional file 2: of MicroRNA Expression in Formalin-fixed Paraffin-embedded Cancer Tissue: Identifying Reference MicroRNAs and Variability.
springer-nature.
2015
Additional file 3: of MicroRNA Expression in Formalin-fixed Paraffin-embedded Cancer Tissue: Identifying Reference MicroRNAs and Variability.
springer-nature.
2015
Additional file 4: of MicroRNA Expression in Formalin-fixed Paraffin-embedded Cancer Tissue: Identifying Reference MicroRNAs and Variability.
springer-nature.
2015
File S1 - Tissue MicroRNAs as Predictors of Outcome in Patients with Metastatic Colorectal Cancer Treated with First Line Capecitabine and Oxaliplatin with or without Bevacizumab.
public-library-of-science.
2014
Focused miRNA panel – miRNAs significantly associated with overall survival..
public-library-of-science.
2014
Focused miRNA panel – miRNAs significantly associated with time to disease progression..
public-library-of-science.
2014
Patient and sample characteristics..
public-library-of-science.
2014
-
hide from search
-
Primary tumor location and bevacizumab effectiveness in patients with metastatic colorectal cancer.
Annals of Oncology.
2013